Search research articles
Contact Us
Filters
Showing results (211-220 of 229) with videos related to
Page
of 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
R Elaidi, A Harbaoui, B Beuselinck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2015
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
S Bracarda, R Iacovelli, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 29, 2015
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
S Bracarda, R Iacovelli, L Boni, et al.
Nature Biotechnology
|
March 1, 1997
Plant-derived vaccine protects target animals against a viral disease
K Dalsgaard, A Uttenthal, T D Jones, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 31, 2002
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol
A Riccardi, O Mora, C Tinelli, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2024
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
R J Motzer, C Porta, M Eto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
ESMO Open
|
July 19, 2023
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study
V Internò, F Massari, R Rudà, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T Pressiani, C Boni, L Rimassa, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 229) with videos related to
Sort By:
Page
of 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
R Elaidi, A Harbaoui, B Beuselinck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2015
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
S Bracarda, R Iacovelli, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 29, 2015
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
S Bracarda, R Iacovelli, L Boni, et al.
Nature Biotechnology
|
March 1, 1997
Plant-derived vaccine protects target animals against a viral disease
K Dalsgaard, A Uttenthal, T D Jones, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 31, 2002
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol
A Riccardi, O Mora, C Tinelli, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2024
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
R J Motzer, C Porta, M Eto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
ESMO Open
|
July 19, 2023
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study
V Internò, F Massari, R Rudà, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T Pressiani, C Boni, L Rimassa, et al.
Page
of 23